Mainly affecting the ageing population, Alzheimer’s disease (AD) is a
chronic neurodegenerative disease characterized by the impairment
of cognitive functions such as memory, thinking and behaviors.
Currently, the single targeted anti-AD drugs have low efficacy and
can only improve the symptoms. Therefore, further research and
development of more efficacious and disease-modifying agents
for the prevention, treatment and restoration of neurodegenative
disorders will have tremendous scientific and economic values.
PolyU has developed a series of dimers derived from tacrine, a
drug currently used for treating Alzheimer’s disease. These dimers
are multi-targeting drugs which can inhibit acetylcholinesterase and
anti-neurotoxicity. When compared with the existing drugs, these
novel multifunctional dimers have shown more promising anti-AD
effects on models with AD in vitro and in vivo.